Order Article Reprints

Hopkins AM, Kichenadasse G, Abuhelwa AY, McKinnon RA, Rowland A, Sorich MJ. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers. 2021; 13(5):1176. https://doi.org/10.3390/cancers13051176

Hopkins, Ashley M., Ganessan Kichenadasse, Ahmad Y. Abuhelwa, Ross A. McKinnon, Andrew Rowland, and Michael J. Sorich. 2021. "Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial" Cancers 13, no. 5: 1176. https://doi.org/10.3390/cancers13051176

Hopkins, A. M., Kichenadasse, G., Abuhelwa, A. Y., McKinnon, R. A., Rowland, A., & Sorich, M. J. (2021). Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers, 13(5), 1176. https://doi.org/10.3390/cancers13051176